Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK-500,001 in COPD
NCT00263874Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing UK-500,001 with Placebo (2 arms). Primary endpoint: Forced Expiratory Volume in 1 Second at 6 weeks. Started Nov 2005; status: terminated.
02
Drugs
UK-500001
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00263874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263874.